Compare Alcon AG (ALC) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Sprott Uranium Miners ETF — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Sprott Uranium Miners ETF trades at $51.24. The key difference: Alcon AG pays a 0.54% dividend while Sprott Uranium Miners ETF pays none. Which is the better fit depends on your goals.
| ALC | URNM | |
|---|---|---|
Market Cap | $32.69B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $92.22 | $83.99 |
52-Week Low | $62.02 | $44.14 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
URNM trades at $53.56, up 1.38% today, but technical indicators signal a bearish trend with moving averages showing strong sell signals. The ETF is positioned at the intersection of AI-driven electricity demand and nuclear energy growth, with recent news highlighting uranium's role in powering data centers. Key support lies at $52, while resistance is near $54.
Outlook is mixed: long-term growth is supported by nuclear energy demand, but short-term risks include volatility in uranium prices and miner equity valuations. Investment opportunity hinges on the AI power narrative, yet caution is warranted due to technical weakness and concentrated miner exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
